ReviewCancer cell international2025
Mechanisms and therapeutic strategies for immunotherapy resistance in gastric cancer.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gastric cancer (GC) is one of the most common and deadly types of cancer worldwide. In China, it is the most frequently occurring digestive tract tumour. Compared to traditional chemotherapeutic regimens centred on platinum and fluorouracil, immunotherapy has become one of the most important treatments for gastric cancer. Immune checkpoint inhibitors (ICIs) have the potential to benefit patients in the long term, but their development is limited by a high rate of resistance. To improve the efficacy of ICIs, it is important to understand the resistance mechanism in GC patients. In this paper, we review the resistance mechanisms of ICI in gastric cancer patients from four aspects: tumour immunity, immunosuppressed TME, tumour cells, and microbial populations.Additionally, we discuss new strategies and ideas to address ICI resistance in gastric cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.